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Abstract
Background: Endothelial dysfunction occurs in patients with end-stage renal disease (ESRD) and is associated with
increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA) contributes to endothelial
dysfunction in ESRD. In the general population, angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) decrease ADMA levels, but no study has compared the effect of these drugs in patients
with ESRD on maintenance hemodialysis (MHD).
Methods: We evaluated the effect of 1-week treatment with ramipril (5 mg/d), valsartan (160 mg/d), and placebo
on ADMA levels in 15 patients on MHD in a double-blind, placebo-controlled, three x three cross-over study.
Results: We found that ADMA levels were increased at baseline and throughout the dialysis session during ramipril
treatment (p < 0.001 compared to both, placebo and valsartan). Ramipril did not increase ADMA levels in a study of
patients without ESRD, suggesting that factors related to ESRD or hemodialysis contribute to the ACE inhibitor-induced
increase in ADMA. We have previously shown that ACE inhibition increases bradykinin (BK) levels during hemodialysis.
We therefore evaluated the effect of bradykinin on ADMA production in A549 cells; a cell line that expresses BK receptors.
Incubation with BK increased intracellular ADMA concentration through BK B2-receptor stimulation.
Conclusion: These data indicate that short-term ACE inhibition increases ADMA in patients on MHD whereas
ARBs do not. In vitro studies further suggest that this may occur through BK-mediated increase in ADMA
production during ACE inhibition.
Trial registration: Clinicaltrials.gov NCT00732069 August 6 2008 and NCT00607672 February 4 2008
Keywords: Asymmetric dimethylarginine, Hemodialysis, Angiotensin converting enzyme inhibitors, Angiotensin
receptor blocker
Background
Patients undergoing maintenance hemodialysis (MHD)
exhibit accelerated atherosclerosis and are at high risk of
developing cardiovascular events, even after controlling
for traditional risk factors [1–3]. Certain non-traditional
factors, such as oxidative stress and inflammation, have
been implicated in the pathogenesis of atherosclerosis of
end-stage renal disease (ESRD) [4]. We and others have
described that patients on MHD have increased markers
of oxidative stress and inflammation, [5–7] which are
worsened by loss of kidney function and to some extent
with hemodialysis therapy.
Endothelial dysfunction is also commonly present in
patients with ESRD and is associated with an increased
risk of atherosclerotic events [8]. Increased levels of
asymmetric dimethylarginine (ADMA), a potent inhibitor
of endothelial nitric oxide synthase, can contribute to
endothelial dysfunction. ADMA levels correlate with
atherosclerosis and predict morbidity and mortality in
patients with ESRD [9, 10]. Arginine methylation
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occurs as a post-translational modification of proteins
[11]. After protein degradation, symmetric and asymmetric
methylarginines are released and transported out of the cell
through cationic amino-acid transporters [12]. Elimination
of symmetric dimethylarginine (SDMA) occurs primarily
through glomerular filtration, whereas ADMA elimination
depends on enzymatic degradation. Two enzymatic path-
ways are important in the elimination of ADMA:
dimethyl-arginine dimethylamino-hydrolases (DDAH),
enzymes expressed in brain, kidney and liver, the alanine
glyoxylate aminotransferase 2 (AGXT2), a mitochondrial
enzyme highly expressed in the kidney and liver [13–15].
Regardless of the mechanism of elimination, plasma levels
of SDMA and ADMA are increased in patients with
chronic kidney disease (CKD) and ESRD [11, 16].
ADMA may also impair endothelial function by
activating the renin-angiotensin system [17]. Conversely
angiotensin II increases ADMA levels through activation
of the NADPH oxidase [18]. Previous studies have shown
that treatment with angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) re-
duce ADMA levels in the general population [19–22]. To
date, no study has compared the effects of ARBs or ACE
inhibitors on ADMA levels in patients with ESRD. Based
on studies in the general population, we hypothesized that
short-term administration of either an ACE inhibitor or
an ARB would lower ADMA levels in patients with ESRD
undergoing MHD. We also hypothesized that these effects
would be more noticeable during hemodialysis due to
concurrent activation of the inflammatory response. In
order to test this hypothesis, we measured ADMA levels
in a three x three crossover, randomized double blind,
placebo-controlled study designed to evaluate the effects
of 1-week treatment of either ACE inhibitor or ARB.
Methods
Study population
Details of the study have been previously described
(NCT00732069, clinicaltrials.gov) [5]. The study was ap-
proved by the Vanderbilt University Institutional Review
Board. Briefly, adult subjects (18 years or older) with
ESRD undergoing MHD (for at least 6 months) 3 times
per week were included in the study. Patients were
clinically stable with a pre-dialysis potassium levels less
than 5.5 mmol/L and adequately dialyzed (kt/V >1.2)
with polysulphone membranes. Exclusion criteria for the
study were the following: history of active connective
tissue disease, acute infection within 1 month prior to
the study, advanced liver disease, gastrointestinal dysfunc-
tion requiring parental nutrition or active malignancy,
medications such as immunosuppressive drugs within
1 month prior to the study, use of anti-inflammatory medi-
cations other than aspirin less than 325 mg per day, use of
vitamin E at a dose higher than 60 IU per day or vitamin
C higher than 500 mg per day; history of myocardial in-
farction or cerebrovascular event within 3 months prior to
the study, or ejection fraction lower than 40 %, pregnancy,
breastfeeding, history of ACE inhibitor-associated angio-
edema, inability to discontinue ACE inhibitors or ARBs.
Twenty patients participated in the study and signed in-
formed consent. Fifteen patients completed the whole
study. One subject voluntarily withdrew the study after
being consented, and three participants were excluded
due to exclusion criteria (uncontrollable hypertension,
hypotension, and hyperkalemia). One subject was with-
drawn from the study because of an event (cerebral ische-
mic stroke) that was not study related. Participants were
recruited between October 2008 and January 2010; the
study ended on March 2010. Further details of the study
population have been published previously [5]. Additional
file 1: Figure S1 summarizes the patient enrollment process.
Study protocol
The study was a three x three cross-over design, random-
ized, double-blind, placebo-controlled. Patients received
ramipril (King Pharmaceutical, Bristol, TN), valsartan
(Novartis Pharmaceutical, East Hanover, NJ) or placebo
for 7 days. After a washout period of 3 weeks, patients
received another treatment until every patient completed
three treatment arms. The order of treatment was ran-
domized using a three x three orthogonal Latin square
design, as specified in Jones and Kenward [23]. Treatment
was dispensed by Vanderbilt Investigational Drug Services.
Ramipril was administered for 2 days at 2.5 mg/d followed
by 5 mg/d the following 5 days. Valsartan was given at
80 mg/d for 2 days, followed by 160 mg/d the following
5 days. On the seventh day of treatment, patients took the
study medication early in the morning and arrived to the
Clinical Research Center (CRC) at Vanderbilt University
Medical Center for a regular session of hemodialysis.
Blood samples were collected before the beginning of
dialysis, 30 min, 1 h later, at the end of dialysis (4 h)
and 2 h after the end of hemodialysis.
ADMA levels
Blood samples were collected in tubes containing EDTA.
After centrifugation, plasma was immediately collected
and stored at −80 °C until processing for analysis. Levels
of ADMA, SDMA, and arginine were measured by high
performance liquid chromatography (HPLC) with fluores-
cence detection and using monomethyl-arginine as internal
standard. Plasma samples were separated using solid-phase
extraction, and analytes were derivatized with ortho-
phthalaldehyde containing 3-mercaptopropionic acid, as
previously described [24]. Methylarginines levels were also
measured in plasma obtained from participants in clinical
trial NCT00607672 of subjects undergoing cardiac surgery,
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who were randomized to one week treatment with rami-
pril, candesartan or placebo prior to surgery.
Markers of inflammation and oxidative stress
Serum IL-6 concentrations were measured using Luminex
immunoassay. Monocyte chemoattractant protein 1 levels
were measured using a commercial kit (Linco Research,
St. Charles, MO) according to the manufacturer instruc-
tions. Soluble CD40 ligand concentrations were measured
in plasma using an ELISA kit (Quantikin, R&D Systems,
Minneapolis, MN). We measured these inflammatory
markers in our previous study [5]. F2-isoprostanes, which
is a stable and reliable marker of lipid peroxidation, were
measured in plasma using ion gas-chromatophragy mass
spectroscopy (GC/MS), as previously described [25, 26].
Cell culture
Human alveolar adenocarcinoma cells (A549) from pas-
sages four to six were used for the experiments. This cell
line was used due to the constitutively expression of
bradykinin receptors. Cells were cultured in DMEM
medium supplemented with 10 % of fetal bovine serum
at 37 °C. Cells were grown to confluence in 6-well plates
and incubated in 2 ml of serum-free medium for 24 h.
Cells were treated with vehicle, bradykinin (20 nM),
bradykinin + the B2 receptor antagonist HOE-140 (1 μM),
or bradykinin + the B1 receptor antagonist Lys (Des-Arg9-
Leu8) bradykinin (1 μM). At the end of the treatment,
culture medium was collected, centrifuged at 2500 g for
10 min, and stored at −80 °C. Cells were washed three
times with PBS, scraped into PBS, and centrifuged for
5 min at 600xg. Cells were re-suspended in 250 μl of ice-
cold sodium phosphate (100 mM, pH 6.5) and sonicated
on ice. Cell lysate (220 μl) was mixed with 220 μl of per-
chloric acid (1.2 M), centrifuged at 2000 g for 10 min at
4 °C, and the supernatant collected and stored at −80 °C
until further processing. Data was normalized by total
protein content in the cells lysate and measured with
the Pierce® BCA kit (Thermo Scientific, Rockford IL)
according the manufacturer protocol.
Statistical analysis
Sample size was calculated based on the effect of treat-
ment on IL-6 concentrations with 95 % power to detect
a 30 % difference between ACEi and ARB. Data was pre-
sented as mean +/− standard error of the mean (SEM).
A linear mixed effect model was used to compare the
effect of treatment (ACEi, ARB, or placebo) during
hemodialysis (time) on ADMA, SDMA, arginine and
arginine to ADMA ratios. The model was selected based
on the lower Akaike’s information criteria. ADMA levels
and arginine-to-ADMA ratios were correlated with markers
of inflammation and oxidative using Spearman’s rank
correlation test. A two side P < 0.05 was considered
significant. Data analysis was performed using SPSS
software (v. 20.0, IBM).
Results
Baseline patient demographics
Fifteen subjects were included in the study. Table 1 sum-
marizes the demographic characteristic of the hemodialysis
study participants. Causes of ESRD were diabetes mellitus
(28 %, n = 4), hypertension (60 %, n = 9), non-steroidal
anti-inflammatory drug (NSAID)-induced glomeruloneph-
ritis (6 %, n = 1), and unknown (6 %, n = 1).
Effect of treatment on blood pressure and heart rate
Systolic and diastolic blood pressure prior to the begin-
ning of dialysis was not different among the treatment
arms (Table 2). Heart rate was also comparable among
the treatment arms (Table 2).
Effect of hemodialysis and treatment on methylarginines
ADMA and SDMA levels decreased by 30 min, reached
a nadir at 1 h after the initiation of hemodialysis (Fig. 1),
and remained lower at the end of hemodialysis (4 h). In
contrast, SDMA reach the lowest level at the end of
hemodialysis. Methylarginines levels increased 2 h after
the end of hemodialysis but remained lower than base-
line levels (14 and 27 % lower than baseline for ADMA
and SDMA respectively). ADMA levels were signifi-
cantly higher at baseline and throughout dialysis during
ramipril treatment (Fig. 1) compared to treatment with
either placebo or valsartan. Treatment with ramipril or
valsartan did not affect SDMA levels.
Effects of hemodialysis and treatment on arginine and
arginine to ADMA ratio
Arginine levels also decreased during hemodialysis,
reaching the lowest level at the end of hemodialysis; 2 h
Table 1 Baseline characteristics
Parameter Value
Age (yr) 50.5 ± 3.1
Gender (male:female) 7:8
Race (African-American: Caucasian: Hispanic) (11:2:2)
Smoker (yes:no) (5:10)
Hypertension (yes:no) 15:0
Previous ACEi or ARB use (yes:no) 3:12
BMI (kg/m2) 30.2 ± 2.0
Calcium x Phosphate product (mg2/dl2) 53.3 ± 3.3
Hemoglobin (g/dl) 11.9 ± 0.3
Erythropoietin dose (units) 5111.1 ± 1488.4
Heparin dose (units) 4800 ± 579.0
Data are presented as mean ± SEM
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later arginine levels returned to pre-dialysis levels (Fig. 2).
Treatment with ramipril or valsartan did not affect
arginine levels (Fig. 2). Arginine-to-ADMA ratios were
lower in patients treated with ramipril at the beginning
of hemodialysis and did not change during dialysis
(Fig. 2). Conversely, treatment with either valsartan or
placebo increased the arginine-to-ADMA ratio during
hemodialysis.
Correlation of ADMA with markers of inflammation and
oxidative stress
ADMA levels correlated positively with markers of
inflammation including interleukin-6 (IL-6; ρ = 0.23,
p = 0.001), monocyte chemoattractant protein-1 (MCP-1;
ρ = 0.27, p < 0.001), and soluble CD 40 ligand (sCD40L;
ρ = 0.22, p = 0.001). The arginine-to-ADMA ratio corre-
lated negatively with the same markers of inflammation;
IL-6 (ρ = −0.26, p < 0.001), MCP-1 (ρ = −0.29, p < 0.001),
and sCD40L (ρ = −0.34, p < 0.001). The ratio also
correlated negatively with F2-Isoprostanes (ρ = −0.31,
p < 0.001), a marker of oxidative stress.
Effect of ramipril on methylarginines levels in patients
with no history of ESRD
To evaluate if ramipril increases ADMA levels in pa-
tients with no history of ESRD, methylarginines levels
were measured in subjects that were treated for 1 week
Table 2 Blood pressure and heart rate prior to the beginning of
hemodialysis
Parameter Placebo Ramipril Valsartan
SBP 134.3 ± 7.4 137.4 ± 7.4 141.1 ± 1.7
DBP 77.0 ± 3.5 75.5 ± 3.7 74.4 ± 3.2
Heart rate 76.7 ± 4.1 75.5 ± 4.0 75.5 ± 3.7
Data are presented as mean ± SEM
Fig. 1 Effect of 1 week treatment with ramipril, valsartan and placebo on (a) asymmetric dimethylarginine (ADMA) and (b) symmetric dimethylarginine
in patients with end-stage renal disease during hemodialysis
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with ramipril, candesartan, or placebo (NCT00607672)
[27]. Additional file 2: Table S1 summarizes the baseline
demographic characteristics among the three treatment
groups. One- week treatment with ramipril did not
affect levels of ADMA, SDMA, or arginine (Fig. 3).
Bradykinin increases ADMA level in human alveolar
adenocarcinoma cells
ACE inhibitors, but not ARBs, increase bradykinin
levels. Thus, we evaluated the effect of bradykinin on
ADMA in human alveolar adenocarcinoma cells (A549),
a cell line that expresses bradykinin receptors. A549 cells
were incubated in the presence bradykinin and bradyki-
nin receptors inhibitors. ADMA levels increased with in-
cubation of bradykinin. Co-incubation with bradykinin
B1 receptor inhibitor had no role in decreasing ADMA,
whereas bradykinin B2 receptor inhibition reduced intra-
cellular ADMA levels (Fig. 4).
Discussion
This study examined the effects of ACE inhibitor and
ARB on methylarginines in patients undergoing MHD.
We found that short-term treatment with ramipril
(1 week) increased ADMA levels and decreased the
arginine-to-ADMA ratio compared to placebo and valsar-
tan in patients undergoing MHD. Studies in vitro suggest
that increase in ADMA production occur through stimula-
tion of bradykinin B2 receptors.
ADMA levels are increased in patients undergoing
MHD and correlate with all-cause mortality [9]. In
addition, ADMA levels correlate positively with markers
of atherosclerosis such as carotid intima-media thick-
ness, left ventricular hypertrophy, and cardiovascular
events [9, 10, 28, 29]. Arginine and ADMA are substrate
and inhibitor of endothelial nitric oxide synthase, re-
spectively; thus the ratio of arginine to ADMA may
modify the enzyme activity [30]. Accordingly, a lower
Fig. 2 Effect of 1 week treatment with ramipril, valsartan and placebo on (a) arginine levels and (b) ratios of arginine- to-asymmetric dimethylarginine
(ADMA) in patients with end-stage renal disease during hemodialysis
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arginine to ADMA ratio has been also been associated
with all-cause mortality and carotid intima-media thick-
ness in the general population [31–33]. While the patho-
genic role of ADMA in the cardiovascular disease is
somewhat unclear, it has been shown to induce
endothelial dysfunction, which is involved in the initi-
ation and progression of atherosclerosis [34]. Another
possible factor that can contribute to increase cardiovas-
cular risk is the over-activation of the sympathetic
nervous system by ADMA. Experiments in humans have
shown that nitric oxide inhibition results in the activa-
tion of the sympathetic nervous system [35], a known
risk factor cardiovascular disease. In fact, ADMA levels
strongly correlates with norepinephrine levels in patients
with ESRD [36].
We did not find any effect of either ramipril or can-
dersatan on ADMA levels in patients with preserved
kidney function. But previous studies demonstrated that
both ACE inhibitors and ARBs reduce ADMA levels in
patients without kidney disease [19–22]. The duration of
the treatment, one week vs. several weeks and months,
may explain why neither ACE inhibitor nor ARB reduce
ADMA levels in our study. Longer treatment with ACE
inhibitors or ARBs may decrease ADMA by decreasing
angiotensin II effects. Angiotensin II increases ADMA
levels in smooth muscle cells by direct stimulation of
AT1 receptors and by increasing oxidative stress [18].
The latter is probably mediated through the production
of reactive oxygen species by NADPH oxidase [37, 38].
Only one previous study in patients on MHD showed
that 6-week treatment with valsartan or amlodipine re-
duced ADMA and SDMA [39]. Findings from this study
were attributed to a reduction in shear stress, which has
Fig. 3 Effect of 1 week treatment with ramipril, candesartan and placebo on (a) asymmetric dimethylarginine (ADMA), b symmetric dimethylarginine,
c arginine levels, and (d) arginine-to-asymmetric dimethylarginine (ADMA) ratios in patients with no history of end-stage renal disease
Fig. 4 Effect of bradykinin (BK, 20nM) incubation on intracellular
asymmetric dimethylarginine (ADMA) levels in human adenocarcinoma
cell (A549). HOE stands for HOE-140, a bradykinin B2 receptor inhibitor
(1 μM). Bradykinin B1 inhibition (B1 inh) was performed using the B1
receptor antagonist Lys (Des-Arg9-Leu8) BK (1 μM). Bars represent
mean ± standard deviation
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been shown to increase ADMA release from endothelial
cells [40]. In comparison, we did not find reduction in
ADMA after 1 week treatment with valsartan. Again, it
is possible that a longer treatment with ARB may have
an effect on ADMA levels. Nevertheless, our study is the
first one to compare the effect of ACE inhibitors and
ARBs on ADMA levels in patients on MHD.
In this study we found that ramipril, an ACE inhibitor,
but not valsartan, an ARB, increased ADMA level. We
found also that ramipril did not increase ADMA level in
patients without ESRD, suggesting that other factors per-
taining to ESRD, particularly hemodialysis may contrib-
ute to the ramipril-induced increase in ADMA levels. A
potential explanation as to why ACE inhibitors and
ARBs differ in their effect on ADMA levels could be that
these medications also differ in their effect on the
degradation of bradykinin. Specifically, ACE inhibitors
increase bradykinin bioavailability, [41] whereas ARBs
does not. We have previously shown that ramipril treat-
ment increased bradykinin levels during hemodialysis
[5]. Previous studies have shown that bradykinin in-
creases reactive oxygen species production through
stimulation of NADPH oxidases [42]. NADPH activation
increases ADMA levels by increasing protein methyla-
tion and inhibiting ADMA degradation, [18, 43] which
are both mediated by reactive oxygen species. Thus, it is
possible that ramipril increases ADMA levels by increas-
ing bradykinin and oxidative stress. Our in vitro studies
support this hypothesis. We found that bradykinin
contributes to ADMA production in human adenocar-
cinoma cells. Importantly, we also found that incubation
with the bradykinin B2 receptor antagonist HOE-140 re-
duces intracellular ADMA levels. Bradykinin B1 receptor
blockage does not play a role in decreasing ADMA
levels suggesting that bradykinin-dependent ADMA pro-
duction occurs through bradykinin B2 receptor stimula-
tion. A possible mechanism that has not been explored
is the role of bradykinin on DDAH, the enzyme respon-
sible for ADMA degradation. Bradykinin may increase
ADMA levels by decreasing DDAH activity.
We also found that markers of inflammation positively
correlate with ADMA levels and inversely with the
arginine-to-ADMA ratio. The latter also has an inverse
correlation with F2-Isoprostanes. These findings are in
agreement with previous studies that showed the cor-
relation between ADMA and inflammatory markers
(C-reactive protein and IL-6) [10, 44]. We previously de-
scribed that ramipril has a greater pro-inflammatory effect
in patients with ESRD [5]. Given the interrelation between
ADMA and inflammation, it is not surprising that ACE
inhibitors also increase ADMA levels in patients on MHD.
Our findings may some interesting implications. First
and foremost, these data could explain the relative lack
of efficacy of ACE inhibitors in improving cardiovascular
outcomes in patients with ESRD, at least to some extent.
To date, there are no clear-cut clinical guidelines for the
use of ACE inhibitor or ARBs in patients with ESRD,
mostly due to lack of randomized clinical trials. If any-
thing, limited epidemiological data on this subject indi-
cate that use of ACE inhibitor could be detrimental in
patients with ESRD, at least when used in combination
[45]. Accordingly, further studies are necessary to exam-
ine the appropriate use of these potentially useful classes
of cardiovascular medications. In addition, these data
demonstrate that patients with ESRD, particularly ones
on MHD behave differently in response to medications
commonly used in the general populations. Accordingly,
one should not simply assume that what has been ob-
served in response to a medication in the general popu-
lation can be safely extrapolated to patients with ESRD.
Finally, our data once again highlight the importance of
the so-called non-traditional cardiovascular risk factors
in patients with ESRD. While this particular study focused
on ACE inhibitors and ARBs, other interventions that
modulate one or more of these metabolic derangements
should be aggressively studied in patients with ESRD.
The strengths of the study are its design, a cross-over
study that eliminates the within-subject variation, and
the biological relevance of the findings. Study limitations
include the short-duration of treatment (1 week) and a
small sample size. It is notable that we nevertheless had
sufficient statistical power to demonstrate significant
differences. Finally, the levels of methylarginines are
somewhat different from other published studies although
there is a wide variability in terms of blood concentrations
of ADMA and SDMA in ESRD patient population. In this
study, we only used high-flux dialyzers, which may affect
the removal of methylarginines. Although a previous study
showed the type of dialyzer does not affect plasma ADMA
removal, [46] the choice of dialyzer could explain the
differential pre-dialysis levels in methylarginines compared
to other published studies [9, 10, 47]. Nevertheless, use of
same subjects as their own controls in this study should
compensate for any difference on baseline level of methy-
larginines and the comparative effects of ACE inhibitor
and ARB administered throughout the study.
Conclusions
In conclusion, we found that short-term ACE inhibitor and
ARB administration differentially affects ADMA levels and
the arginine-to-ADMA ratio in patients undergoing MHD.
These parameters also correlate with markers of inflamma-
tion and oxidative stress. While these data suggest that
ARB therapy may be a better treatment option for
improving non-traditional cardiovascular risk factors in pa-
tients on MHD, further studies are required to determine
the real therapeutic benefit of these interventions in order
to reduce atherosclerotic burden in this patient population.
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